Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Exclusion Criteria

• •1. Women who are pregnant or lactating. Patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures
• •2. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV infected persons
• •3. Patients known to have varicella or herpes zoster virus infection
• •4. Previous exposure to any anti-tumor therapy
• •5. Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than two fold of upper normal level,Ccr# 50 mL/min unless these abnormalities were related to the lymphoma
• •6. History of DVT or PE within past 12 months
• •7. Poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/L or platelet count less than 75×109/L, unless caused by bone marrow infiltration
• •8. New York Heart Association class III or IV cardiac failure; or Ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome#acute heart failure#severe ventricular arrhythmia
• •9. CNS or meningeal involvement
• •10. Known sensitivity or allergy to investigational product
• •11. Major surgery within three weeks
• •12. Patients receiving organ transplantation
• •13. Patients with secondary tumour, excluding cured (5 years without relapse) in situ Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer, Gastrointestinal intramucous carcinoma and breast cancer
• •14. Presence of Grade III nervous toxicity within past two weeks
• •15. Active and severe infectious diseases
• •16. Any potential drug abuse, medical, psychological or social conditions whichmay disturb this investigation and assessment
• •17. In any conditions which investigator considered ineligible for this study.